John P. Leonard

Active 1979–2025

171
Papers
30,706
Citations
93
h-index
165
i10-index

Citations

Citations per year for John P. Leonard1973: 1 citations1981: 2 citations1982: 3 citations1983: 1 citations1984: 8 citations1985: 5 citations1986: 3 citations1987: 2 citations1988: 5 citations1989: 3 citations1990: 2 citations1991: 5 citations1992: 27 citations1993: 33 citations1994: 28 citations1995: 39 citations1996: 44 citations1997: 51 citations1998: 84 citations1999: 65 citations2000: 52 citations2001: 65 citations2002: 69 citations2003: 93 citations2004: 89 citations2005: 127 citations2006: 99 citations2007: 144 citations2008: 148 citations2009: 130 citations2010: 183 citations2011: 224 citations2012: 213 citations2013: 216 citations2014: 207 citations2015: 232 citations2016: 156 citations2017: 198 citations2018: 215 citations2019: 720 citations2020: 845 citations2021: 913 citations2022: 928 citations2023: 690 citations2024: 1,209 citations2025: 580 citations2026: 16 citations1974–1980: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,947 citing papers, 30.8% of this breakdownChina: 986 citing papers, 7.7% of this breakdownUnited Kingdom: 838 citing papers, 6.5% of this breakdownGermany: 799 citing papers, 6.2% of this breakdownItaly: 703 citing papers, 5.5% of this breakdownFrance: 587 citing papers, 4.6% of this breakdownCanada: 517 citing papers, 4% of this breakdownSpain: 387 citing papers, 3% of this breakdownSwitzerland: 369 citing papers, 2.9% of this breakdownAustralia: 367 citing papers, 2.8% of this breakdownNetherlands: 342 citing papers, 2.7% of this breakdownJapan: 335 citing papers, 2.6% of this breakdown
0%30.8%Other 20.7%

Fields

  • Medicine57.6%
  • Biochemistry, Genetics and Molecular Biology27.9%
  • Immunology and Microbiology8.4%
  • Neuroscience3.4%
  • Engineering0.4%
  • Computer Science0.4%
  • Other1.9%

Topics

  • Lymphoma Diagnosis and Treatment10.5%
  • CAR-T cell therapy research4.9%
  • Chronic Lymphocytic Leukemia Research4.8%
  • Immune Cell Function and Interaction3%
  • Viral-associated cancers and disorders2.3%
  • CNS Lymphoma Diagnosis and Treatment2.2%
  • Other72.3%

Coauthors

All papers

Open in search
  1. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 1,633

  2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  3. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew D. Zelenetz, John P. Leonard, Nancy L. Bartlett, Bao Tran, Jyoti Shetty, Yongmei Zhao, Dan Soppet, Stefania Pittaluga, Wyndham H. Wilson, Louis M. Staudt - New England Journal of Medicine 2018 cited by 2,261

  4. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 166

  5. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2010 cited by 853

  6. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 251

  7. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 421

  8. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 423

  9. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

    Authors: , , , , , , , , , - 1997 cited by 814

  10. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    Authors: , , , , , , - New England Journal of Medicine 2010 cited by 1,353

  11. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 117

  12. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 737

  13. Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 164

  14. Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

    Authors: , , , , , , , , - Leukemia & lymphoma/Leukemia and lymphoma 2020 cited by 93

  15. Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kristie A. Blum, Anamarija M. Perry, Alexandra E. Kovach, David Hodgson, Louis S. Constine, Lale Kostakoglu Shields, Anca Prica, Hildy Dillon, Richard F. Little, Margaret A. Shipp, Michael Crump, Brad S. Kahl, John P. Leonard, Sonali M. Smith, Joo Y. Song, Kara M. Kelly, Jonathan W. Friedberg - New England Journal of Medicine 2024 cited by 200

  16. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhengming Chen, Bhoomi Mehrotra, Tomas G. Neilan, Richard M. Steingart - European Heart Journal 2023 cited by 48

  17. Postibrutinib outcomes in patients with mantle cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 283

  18. Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 150

  19. Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , - Cancer Discovery 2014 cited by 272

  20. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , André Goy, Mitchell R. Smith, Stephen M. Ansell, John Kuruvilla, Martin Dreyling, Catherine Thiéblemont, Richard F. Little, Igor Aurer, Marinus H. J. van Oers, Kenichi Takeshita, Ajay K. Gopal, Simon Rule, Sven de Vos, Ioana Kloos, Mark Kaminski, Michel Meignan, Lawrence H. Schwartz, John P. Leonard, Stephen J. Schuster, Venkatraman Seshan - Annals of Oncology 2017 cited by 377

  21. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 94

  22. Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 128

  23. Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2013 cited by 214

  24. A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology

    Authors: , , , , , , , , , , , , , , , , - Stem Cell Reports 2019 cited by 78